UNSPSC 51142540: Amantadine hydrochloride

This classification denotes an antiviral agent and cation channel blocker with the molecular formula C10H17N.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M6Q1EO9TD0, chemically known as 1-aminotricyclo(3.3.1.1(sup 3,7))decane but more generally known as amantadine hydrochloride, which bears US NIH Compound Identifier 2130. European Medicines Agency schedules Amantadine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00422MIG.

Most nations, for tariff and trade purposes, schedule amantadine hydrochloride under HS 29213000 and SITC 51453. As of Q4 2014, AMANTADINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Amantadine hydrochloride bears US NLM identifiers UMLS ID C0723562 and NCI Concept Code C28818. SMILES: C1[C@@H]2CC3C[C@H]1C[C@](C2)(C3)N.CL.

UNSPSC 51142540 Amantadine hydrochloride is a Commodity code that encompasses the procurement of specific pharmaceutical products by state and local health agencies, though recent solicitation activity under this code shows minimal alignment with amantadine as a discrete product line. State and local buyers posting under pharmaceutical commodity codes typically include county health departments, state health and human services agencies, and cooperative purchasing alliances administering multi-jurisdictional drug procurement. The actual solicitations tagged to this code reflect broader pharmaceutical and over-the-counter product procurement rather than amantadine-specific buys—vendors responding to these opportunities supply managed distribution through authorized pharmaceutical wholesalers, must maintain current Good Manufacturing Practices (cGMP) and Drug Supply Chain Security Act (DSCSA) compliance, and accept fixed-fee, net-price, or WAC-minus pricing models depending on the contract structure.

Recent activity appears concentrated in the upper Midwest and Southeast, with the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administering a two-year RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson across participating state and local facilities including Oregon; Seminole County, Florida issued an IFB (IFB60459723LAS) in June 2026 for naloxone and drug deactivation systems with quarterly deliveries; and the Texas Health and Human Services Commission released an RFI (HHS0017013) in April 2026 exploring direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. The code shows limited recent activity specifically for amantadine; pursue this code only if your firm manufactures or distributes amantadine through authorized pharmaceutical wholesalers and can meet cGMP, DSCSA, insurance, and compliance requirements typical of state cooperative and county health procurement.